Table 2.

Plasma lipid changes by drug assignment and myalgia status^a,b.

	Nonmyalgic sample (n = 77)		Myalgic sample (n = 38)
	Simvastatin	Placebo	Simvastatin	Placebo
ΔTC, mmol/L	−1.50 ± 0.84∗	−0.04 ± 0.58	−1.67 ± 0.61∗	−0.03 ± 0.70
ΔLDL-C, mmol/L	−1.44 ± 0.67∗	−0.01 ± 0.50	−1.51 ± 0.60∗	−0.14 ± 0.60
ΔHDL-C, mmol/L	0.08 ± 0.18∗	−0.01 ± 0.15	0.04 ± 0.18	0.02 ± 0.14
ΔTG, mmol/L	−0.65 ± 2.47∗	0.04 ± 1.66	−1.00 ± 2.50∗	0.48 ± 2.73

^aData are means ± SD; Δ = absolute change from before to after the treatment intervention.

^bLDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. ^∗ P < 0.01 from baseline. There were no differences (P ≥ 0.18) between nonmyalgic and myalgic participants within a treatment group.